Support Grows for Neurostimulation Research
The company Nexalin is commending recent congressional momentum in support of deep brain neurostimulation research. The company noted the potential for such research to benefit veterans and other individuals with neurological disorders.
- The "Expanding Veterans’ Access to Emerging Treatments Act" (H.R. 7091), introduced on January 15, 2026, proposes the expansion of clinical trials for deep brain neurostimulation and the creation of a compassionate use pathway within the VA system. - Unlike traditional Deep Brain Stimulation (DBS) which requires surgical implants, Nexalin's technology, known as Deep Intracranial Frequency Stimulation (DIFS™), is non-invasive and uses a frequency-based waveform to stimulate deep brain structures. - Military personnel and veterans face a higher risk of traumatic brain injury (TBI), dementia, and comorbid neuropsychiatric conditions like PTSD, which can create a negative feedback loop, increasing the risk of other conditions such as Alzheimer's Disease. - A key piece of related legislation, House Report 119-271, which was signed into law, expands NIH-supported research using deep brain stimulation in non-human primates to study Alzheimer's and Parkinson's disease. - Nexalin is currently conducting a clinical trial with the University of California, San Diego, to assess its Gen-3 Halo headset, a home-use device, for treating mild traumatic brain injury in veterans. - The market for deep brain stimulation devices is projected to grow from $1.2 billion in 2023 to $1.9 billion by 2030, while the broader neuromodulation device market is expected to exceed $10.7 billion in the same timeframe. - Research has shown that DBS can be a safe and effective treatment for PTSD in veterans, with some studies reporting symptom reductions of up to 79%. - From February 22-24, 2026, the American Academy of Neurology held its "Neurology on the Hill" event, where 200 neurologists lobbied lawmakers to maintain federal funding for brain research initiatives.
